Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus: A Subgroup Analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
This is a prospective evaluation of the effect of structured care of dyslipidemia with atorvas tatin (strict implementation of guidelines) versus usual care (physician's standard of care) on morbidity and mortality of patients with coronary heart disease (CHD) and diabetes mellitus (DM). From 1600 consecutive CHD patients randomized to either form of care in the GREek Atorvastatin and CHD Evaluation Study (GREACE), 313 had DM: 161 in the structured care arm and 152 in the usual care arm. All patients were followed up for a mean of 3 years. In the structured care group, patients were treated with atorvastatin to achieve the National Cholesterol Education Program (NCEP) low-density lipoprotein cholesterol (LDL-C) treatment goal of < 2.6 mmol/L (100 mg/dL). Primary endpoints were all-cause and coronary mortality, coronary morbidity, and stroke. In the structured care group, 156 patients (97%) were taking atorvastatin (10-80 mg/day; mean, 23.7 mg/day) throughout the study; the NCEP LDL-C treatment goal was reached by 150 patients (93%). Only 17% (n = 26) of the usual care patients were on long-term hypolipidemic drug treatment and 4% (n = 6) reached the NCEP LDL-C treatment goal. During the study, 46 of 152 (30.3%) CHD patients with DM on usual care experienced a major vascular event or died versus 20 of 161 (12.5%) patients on structured care; relative risk reduction (RRR) 58%, p < 0.0001. RRR for all-cause mortality was 52%, p = 0.049; coronary mortality 62%, p = 0.042; coronary morbidity 59%, p < 0.002; and stroke 68%, p = 0.046. Event rate curves started deviating from the sixth treatment month and the RRR was almost 60% by the 12th month. RRRs remained at that level until the end of the study, when they became statistically significant. The cost/life-year gained with structured care was estimated at US $6200. In CHD patients with DM, structured care of dyslipidemia with atorvastatin to achieve the NCEP LDL-C treatment goal, reduces all-cause and coronary mortality, coronary morbidity, and stroke by more than one half within a 3-year period, in comparison to usual care. Clinical benefit is manifested as early as the sixth month of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In persons with fasting triglycerides of 200 to 499 mg/dL, despite tight adherence to a healthy diet (to include reduced intake of simple carbohydrates and avoidance of fruit juices and alcohol) and optimized glycemia control, prescribe statin therapy to the maximum tolerated dose to achieve goals for non-HDL-C or apo B, since all apo B–containing particles are potentially atherogenic.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [324]
In the citing paper
“Moderate-potency or high-potency statins, possibly combined with cholesterol absorption inhibitors or bile acid sequestrants, are effective for achieving LDL-C, non-HDL-C, and apo B goals in persons with prediabetes.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [324]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
THE DIET AND 15-YEAR DEATH RATE IN THE SEVEN COUNTRIES STUDY
KEYS, A., MIENOTTI, A., KARVONEN, M. J., ARAVANIS, C., BLACKBURN, H., BUZINA, R., DJORDJEVIC, B. S., DONTAS, A. S., FIDANZA, F., KEYS, M. H., et al. (1986) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114480 · Cited by 1,790
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Research works printed but not linked: 6
- American Diabetes Association, 2001, Diabetes Care, 24, S58
- Scandinavian Simvastatin Survival Study (4S) Group, 1994, Lancet, 344, 1383
- National Heart, Lung, and Blood Institute, 2000, Morbidity and Mortality: 2000 Chart Book
- 10.1001/archinte.1997.00440330039004 · doi:10.1001/archinte.1997.00440330039004 · Paper page
- 10.1185/0300799009117026 · DOI
- Youssef F., Angiology
Cited by
Authors/Task Force Members, Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,647
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 878
Athyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
Metadata
- Authors
- Athyros, V. G., Papageorgiou, A. A., Symeonidis, A. N., Didangelos, T. P., Pehlivanidis, A. N., Bouloukos, V. I., & Mikhailidis, D. P.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Greek Society of General Practitioners, Thessaloniki, Greece.
- Diabetes Center of North Greece, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece.
- Atherosclerosis Unit and 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; Greek Society of General Practitioners, Thessaloniki, Greece; Diabetes Center of North Greece, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; and Department of Clinical Biochemistry, Royal Free Hospital, London.
- Venue
- Angiology
- Publisher
- SAGE Publications
- Published
- 2003-11
- Volume
- 54
- Issue
- 6
- Pages
- 679-690
- ISSN
- 0003-3197 (ISSN-L)
- 1940-1574
- OpenAlex
- W2004034044
- Cited by
- 85
- References
- 46
- Citations by year
- 2023: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 5 · 2014: 4 · 2013: 2 · 2012: 4
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Angiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- coronary artery disease, diabetes mellitus, structured care, dyslipidemia, NCEP guidelines, all-cause mortality, coronary heart disease mortality, stroke, lipid-lowering therapy, cost-effectiveness, secondary prevention, cardiovascular risk reduction, cost per life year
- MeSH terms
- Atorvastatin, Anticholesteremic Agents, Coronary Disease, Diabetes Mellitus, Female, Heptanoic Acids, Humans, Male, Middle Aged, Prospective Studies, Pyrroles, Time Factors, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus: A Subgroup Analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. https://app.cochat.ai/papers/10.1177/000331970305400607
- The paper
- Athyros, V. G., Papageorgiou, A. A., Symeonidis, A. N., Didangelos, T. P., Pehlivanidis, A. N., Bouloukos, V. I., & Mikhailidis, D. P. (2003). Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus: A Subgroup Analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. Angiology. https://doi.org/10.1177/000331970305400607
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.